Your browser doesn't support javascript.
loading
From conventional to stealth liposomes: a new Frontier in cancer chemotherapy.
Cattel, L; Ceruti, M; Dosio, F.
Afiliación
  • Cattel L; Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy. luigi.cattel@unito.it
J Chemother ; 16 Suppl 4: 94-7, 2004 Nov.
Article en En | MEDLINE | ID: mdl-15688621
In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Doxorrubicina / Liposomas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2004 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Doxorrubicina / Liposomas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: J Chemother Asunto de la revista: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Año: 2004 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido